Trial intelligence / Profile preview

Maintenance therapy with oral tofacitinib in ulcerative colitis

2011-004580-79Phase 3Completed

Sponsor
Pfizer
Start
Jan 2012
Modality
Small Molecules
Countries
1
01

Overview

A Phase 3 trial of tofacitinib in autoimmune colitis, sponsored by Pfizer. Started Jan 2012; status: completed.

02

Drugs

03

Conditions

autoimmune colitis

Beyond the preview

Go deeper on 2011-004580-79.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2011-004580-79.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call